RxDoctor Payments Data

Danielle McPherson

Nurse Practitioner · Mandan, NDNPI 1427140409

Payments from drug & device makers

$631in general payments, 2019–2025

Across 22 payments — averaging $28.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$124
  • Johnson & Johnson$118
  • Nevro Corp.$115
  • Exact Sciences$89
  • Beone Medicines USA, Inc.$55
  • Astellas Pharma US Inc$37
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$631 in reported general payments places this provider in the 75th percentile of 455 nurse practitioner providers in North Dakota.

See all nurse practitioner providers in North Dakota

Medicare billing

Part B allowed, 2024
$77,846
Medicare patients
286
Services billed
2,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$38,920
EliquisApixaban30$27,465
TrulicityDulaglutide19$18,457
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$6,891
JanuviaSitagliptin Phosphate12$6,812
Breo ElliptaFluticasone/Vilanterol15$5,714
Incruse ElliptaUmeclidinium Bromide11$3,830
Levothyroxine Sodium237$3,445
Losartan Potassium262$2,661
Metoprolol Succinate109$2,158
Atorvastatin Calcium193$2,146
Omeprazole171$2,072
SynthroidLevothyroxine Sodium23$2,072
Rosuvastatin Calcium138$1,880
Simvastatin127$1,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$18,45719 claims
AbbVieSynthroid$32$2,07223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 455 nurse practitioner providers in North Dakota.

Other nurse practitioner in Mandan

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →